Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 3.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,332,411 shares of the company’s stock after purchasing an additional 45,300 shares during the quarter. Two Sigma Advisers LP owned about 0.84% of Ionis Pharmaceuticals worth $53,376,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Great Point Partners LLC acquired a new stake in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $15,728,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Ionis Pharmaceuticals by 8.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock valued at $57,807,000 after purchasing an additional 114,914 shares during the period. DRW Securities LLC bought a new stake in shares of Ionis Pharmaceuticals during the second quarter valued at about $2,429,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Ionis Pharmaceuticals by 13.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company’s stock valued at $26,070,000 after purchasing an additional 77,909 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its holdings in Ionis Pharmaceuticals by 8.9% in the second quarter. Privium Fund Management B.V. now owns 247,267 shares of the company’s stock worth $11,162,000 after purchasing an additional 20,274 shares during the period. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $38.11 on Friday. The company’s fifty day moving average is $37.63 and its two-hundred day moving average is $42.28. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a 12-month low of $33.33 and a 12-month high of $54.44.

Insider Activity at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares in the company, valued at approximately $6,369,303.65. The trade was a 3.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Swayze sold 1,194 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the transaction, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,877 shares of company stock valued at $299,578. Company insiders own 2.71% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on IONS. Piper Sandler dropped their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. JPMorgan Chase & Co. boosted their target price on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Wells Fargo & Company decreased their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Guggenheim lowered their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Finally, StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $60.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.